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Melphalan tissue concentrations in patients treated with regional isolated
perfusion for melanoma of the lower limb
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Departments of'Surgery' and 2Pharmacology, The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Amsterdam,
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Smmary In 14 consecutive patients with recurrent melanoma of the lower limb a total of 35 biopsies were
taken at the end of perfusion treatment to assess melphalan tissue concentrations in tumour, skin/subcutis and
muscle tissue. In tumour tissue (n = 12) the mean melphalan concentration was 6.8 pg g-', which was
significantly higher than that of healthy skin/subcutis (3.2 zg g-'; n = 10), but equal to that of muscle tissue
(6.5 pg g-'; n = 13). The correlation between melphalan concentration in the tissues and the concentration in
the perfusate was studied. The latter was assessed in the form of melphalan peak concentration and the area
under the curve (AUCO,60) of the melphalan concentration-time curve. Tumour concentration proved to be
correlated linearly with AUCO-.w (R = 0.6, P = 0.002) and muscle concentration with melphalan peak concen-
tration (R = 0.8, P = 0.04). There was no relation between skin/subeutis concentrations and the perfusate
parameters. Further research is warranted to study the relationship between melphalan tissue concentration,
tumour response and regional toxicity.
With regional isolated perfusion, high levels of melphalan
can be achieved in the vasculature of a limb with no or
negligible leakage to the systemic circulation (Kroon, 1988).
To assess the amount of cytostatic drug taken up by the
tissues, pharmacokinetic studies have until now been based
mostly on the area under the curve (AUCO.60) of the concen-
tration-time curve of melphalan in the perfusate (Benckhuij-
sen et al., 1985, 1988) (Figure 1). There are, however, limited
data on directly measured melphalan tissue concentrations
(Scott et al., 1990). In this article we present the results of a
study evaluating melphalan tissue concentrations in relation
to perfusate pharmacokinetics.
Patents and methods
Fourteen consecutive patients (12 women, two men; median
age 50 years) with recurrent melanoma of the lower limb
were treated with regional isolated perfusion. Perfusion was
carried out over 1 h at the iliacal or femoropopliteal level
with a median dose of 74 mg of melphalan. The dose was
calculated on the basis of tissue volume (10 mg of melphalan
per litre of perfused tissue). Tissue temperatures during per-
fusion were 'controlled' at a normothermic level, i.e. between
37 and 38°C. Our perfusion technique has been described in
detail elsewhere (Kroon, 1988). Melphalan as single dose was
gradually injected (over one circulation time of the circuit,
i.e. within about 2-3 min) into the arterial line. The total
perfusate volume measured a median of 750 ml with a
haematocrit of about 0.25.
During the perfusion perfusate samples were taken from
the venous line at 5 min intervals and analysed for melphalan
concentration by high-performance liquid chromatography
(HPLC) assay (Chang et al., 1978). Melphalan peak concen-
tration and AUCO.60 were assessed. Tumour, skin/subcutis
and muscle biopsies were taken at the end of perfusion. The
method of analysing the tissue samples was as described by
Scott et al. (1990). The specimens were snap frozen and
stored at -20'C for batch analysis. They were later thawed,
weighed and homogenised in a known volume of acidic
buffer. Duplicate specimens were then assayed by HPLC.
Differences in melphalan concentration between tumour,
skin/subcutis and muscle tissue were pairwise analysed using
the Wilcoxon signed-rank test. Mean values are given with
the standard deviation.
Results
A total of 35 tissue biopsies were taken, consisting of 12
tumour, 10 skin/subcutis and 13 muscle specimens (Table I).
From eight patients three tissue biopsies were available for
analysis. The mean melphalan concentration was 6.8
(4.8) lg g-' for tumour biopsies, 3.2 (2.5) pggI for skin/
subcutis biopsies and 6.5 (3.7)1Lggg' for muscle biopsies.
There was a significant difference in melphalan concentration
between tumour and skin/subcutis biopsies (P = 0.01) as well
as between muscle and skin/subcutis biopsies (P = 0.01).
The mean melphalan peak concentration was 48.9
(18.2)ILgml-' and the mean AUCO.60 1,530 (514) lg
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Fire 1 A pharmacokinetic profile of the melphalan concentra-
tion-time curve in perfusate.
Table I Mean melphalan concentration (s.d.) in the different tissue
biopsies
Melphalan concentration (Lgg-')
Tumour (n = 12) 6.8 (4.8)
Skin (n = 10) 3.2 (2.5)
Muscle (n = 13) 6.5 (3.7)
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Fure 2 Plot of melphalan tumour concentration with AUC
(n = 9, R = 0.6, P= 0.002).
min ml1'. There was a linear relation between melphalan
concentration in tumour tissue and the AUC0,60 (n = 9,
R = 0.6, P = 0.002) (Figure 2), and also between melphalan
concentration in muscle tissue and melphalan peak concen-
tration in perfusate (n = 10, R = 0.8, P = 0.04) (Figure 3).
No correlation could be found between melphalan concentra-
tion in skin/subcutis specimens and the above-mentioned
perfusate parameters.
Dsio
From these results it is concluded that there is a higher
uptake of melphalan in tumour tissue (6.8p1gg-') than in
healthy skin/subcutis (3.2 jgg-'), and data from the
literature support this finding (Luck, 1956; Parsons et al.,
1981). Melphalan (L-phenylalanine mustard) may be taken
up more selectively by melanin-producing cells since
phenylalanine is a metabolite of melanin (Luck, 1956). In
addition, in vitro studies have demonstrated a greater
capacity for melphalan transport into malignant cells (Par-
sons et al., 1981). In the case of human melanoma this
transport is an active and carrier-mediated one (Begleiter et
al., 1980). Our findings, however, contrast with the results
reported by Scott et al. (1990), who found no difference in
mean melphalan concentration between tumour tissue
(3.10 iLg g') and healthy skin (3.54 iLgg-'). In that study the
concentration of melphalan in skin and fat had been
measured separately, showing a significantly lower melphalan
concentration in fat (1.15 Lgg-'), and so our lower mel-
phalan concentration in the skin/subcutis biopsies may be
explained by a different fat component in the present
study.
Since the present series showed that the AUCO,60 was
linearly correlated with the melphalan concentration in
tumour biopsies, this perfusate parameter could provide
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Figwe 3 Plot of melphalan muscle concentration with mel-
phalan peak concentration (n = 10, R = 0.8. P = 0.04).
reliable information on the amount of cytostatic taken up by
tumour tissue. However, the AUCO.60 does not indicate the
level of melphalan uptake by other tissues. It is interesting
that similar values for melphalan tissue concentrations have
been alculated using a computer model based on perfusate
melphalan concentration-time curves. However, this model
does not distinguish between the different tissues (Benckhuij-
sen et al., 1988). The higher melphalan tumour concentration
of the present series, compared with the results of Scott et al.
(1990), may be explained by the smaller perfusate volume
used at our institutes (750 vs 1,200 ml), which could lead to a
higher AUC0,60 and higher melphalan peak concentrations
(Kaase et al., 1992). From these results it seems that the
higher tissue temperatures used by Scott et al. (39-40°C) do
not improve tumour perfusion, which could theoretically
result in higher tissue concentrations.
It is remarkable that melphalan muscle concentration in
the present study correlated with melphalan peak concentra-
tion, since a previous study from our institute indicated that
this perfusate parameter was associated with a stronger toxic
reaction after perfusion (Klaase et al., 1992). Part of this
toxicity has to be attributed to direct muscle damage. In
another study, however, no correlation was demonstrated
between melphalan tissue concentrations and the perfusate
parameters of AUCO0w and melphalan peak concentration
(Byrne et al., 1990).
In conclusion, it seems that regional isolated perfusion
leads to a higher uptake of melphalan in tumour tissue than
in healthy skin/subeutis. Further research is required to study
the relationship between melphalan tissue concentration,
tumour response and regional toxicity.
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